TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Dose of Calcium Supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parenting Stress Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Any severe complication or death
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life as measured by Mini Asthma Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Extent of dermatomal sensory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of sensory loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anatomical extent of injectate spread using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Venous plasma concentration of ropivacaine at periodic time intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toxicities as Assessed Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial perfusion (ml/min/g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating immunity cell profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to discontinuation (TTD) of olanzapine and risperidone therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinus rhythm maintenance one month after cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported urethral pain and related symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: GAD7 scores (anxiety)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction/acceptability post program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ABILHAND Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Adelaide Activities Profile (AAP)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prioritization Cue-related Changes in Neural Representation of Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Working Memory Delay Period Phase-amplitude Coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Covert Spatial Attention-related Changes in Phase-amplitude Coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose of cidofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to IMCI guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Correct disease classification and prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-Causes mortality
Endpoint domain: Mortality/survival
Primary endpoint: Foot temperature data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (QOL) Due to Urinary Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak flow rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastrointestinal Quality of Life Index (GIQLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in SF-36 Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in EQ-5D Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Yield of MNCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of overall intestinal cleaning effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful Expulsion of Fetus and Placenta Within 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Gross Motor Function Measure - 66 (GMFM-66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Elbow Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance (independent) activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Informal caregiver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Occurrence of Urinary tract infection recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in health-related anthropometric measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective measure of degree of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: all causes and specific cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with no alterations of mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endothelial Blebs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic GVHD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in pharmacokinetics of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abscopal effect rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lost work time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD8+ T cell densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative transformation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Grades of Persistent Non-hematological Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: anti-PA2024 immune response in lymph node-derived leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PAP immune response in lymph node-derived leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PA2024 immune response in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PAP immune response in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Weekly Urticaria Activity Score (UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for UA/NSTEMI or STEMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Size of the Adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Muscle fractional synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Balloon Occlusion of Superior Vena Cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With > 20% Decrease in Mean Diurnal Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Participants With > 20% Decrease in Diurnal Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change of Clotting Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Maximum Clot Firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of Clot Formation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of ADPtest of Impedance Aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of TRAPtest of Impedance Aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Segmental wall motion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infarct size estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time-concentration curve to last concentration (AUCt) of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of acetylsalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time-concentration curve to last concentration (AUCt) of acetylsalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trajectory of Serum and Urinary NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption in the first 6 hour period after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption in the first 12 hour period after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption in the first 24 hour period after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Osteoprotegerin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vasodilator Stimulated Phosphoprotein-Phosphorylation (VASP-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pneumonia hospitalization status
Endpoint domain: Mortality/survival
Primary endpoint: Bacterial concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Baseline incidence of variant alleles in ATM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of biopsy necessity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetric Dimethylarginine (ADMA) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best objective tumor response rates (complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in California Verbal Learning Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in children's psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in children's socio-emotional skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Monthly Percentage of Voluntary Abstinent Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly Point Prevalence of Abstinent Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly Drinks per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Vaccine Response to Anti-gE Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine Response for Anti-gE Humoral Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FLU Haemagglutination Inhibition (HI) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with evidence of subglottic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of potentially inappropriate psychotropic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Survival Rate at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: Improved small airways obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean achilles tendon thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TAPSE value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of death from any cause, recurrent myocardial infarction, ischaemia-driven target vessel revascularization, or hospitalization due to NYHA class IV heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Neurochemical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rush Video Rating Scale (mRVRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Categorical Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective cure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite outcome of death from cardiovascular causes or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Safety of Endoscopic Thyroidectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Relative satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Global Survey/Caregiver Global Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distress thermometer
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ceramide levels in exhaled breath condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dose limiting toxicity during cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Participant satisfaction with ASCEND
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant impression of ASCEND as a credible treatment to improve cognition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful closure of neural tube defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleep quality during the night of surgery
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Recovery Self Assessment (RSA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Client Satisfaction Questionnaire-8 (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Empowerment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Borg dyspnea Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of well-being Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: safety and dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac implantable electronic device related infection
Endpoint domain: Adverse events/effects
Primary endpoint: Balance evaluation systems test (BESTest) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children with recurrent wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of children with early aeroallergen sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response rate (confirmed complete and confirmed partial response)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and severity of toxicity as assessed by NCI CTCAE version 3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Regional Oxygen saturation downstream of popliteal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Face Global Aesthetic Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Questionnaire responses
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite of Pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 symptom development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of IBD patients in activity with DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: new decayed surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Frequency and severity of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accrual with intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance with intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time-to-occlusion or stent patency period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of Transient Ischemic Attack (TIA)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Neurologic Injury assessed by Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: surgical indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: early severe hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of improvement in mucosal barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CLABSI Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAP Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preoperative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time Averaged Change From Baseline in Adjudicated Pulmonary Capillary Wedge Pressure (PCWP) During Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Time-Averaged Change From Baseline in Adjudicated Pulmonary Artery Diastolic Pressure (PAD) During the Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Time-Averaged Percent Change From Baseline in Cardiac Index (Fick)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to Home Breathing Exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with chorioamnionitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Numerical rating score for headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nasal chloride secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Brivaracetam (BRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oral Health Self Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CAESAR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative CR Rates Within 16 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aphasia severity as measured by the Western Aphasia Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Fold Increase (GMFR) for Serum HI Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects in Terms of HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Internet Gaming Disorder Scale-Short-Form (IGDS9-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DNA alterations in blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maternal serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apneas and Hypopneas Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days of flushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of the hepatocellular carcinoma after hepatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes